The U.S. Food and Drug Administration (FDA) refused the first NDA for Fintepla in April. In a Refusal to File (RTF) letter, the FDA cited Zogenix’s failure to include non-clinical studies addressing the chronic administration of fenfluramine hydrochloride, Fintepla’s active substance. The agency also said one of the clinical datasets included in the application was incorrect, preventing the completion of the review process required for NDA filing.

Zogenix and FDA reviewed the two issues identified in the RTF letter in a Type A meeting held in May.

Based on that meeting, the FDA agreed that Zogenix can resubmit its application without the need to include new chronic toxicity studies, which had been requested in the RTF letter.

The pharmaceutical company also conducted and discussed with the FDA a root cause analysis to explain the incorrect clinical data included in the first NDA. The FDA agreed that Zogenix may resubmit the datasets in the new NDA.

“We are very pleased with the outcome of our meeting with the FDA and appreciate their thoughtful approach in considering the totality of the data from our drug development program, along with additional clinical and non-clinical literature that will be referenced in our resubmission,” Stephen J. Farr, PhD, president and CEO of Zogenix, said in a press release.

“We now have the clarity required to successfully resubmit our Fintepla NDA, which we anticipate will occur in the third quarter,” he added.

However, this rescission is not expected to limit the potential for Priority Review status for Zogenix’s resubmitted NDA.

Breakthrough therapy designation is intended to accelerate the development and review of a potential therapy for a serious or life-threatening disease, with clinical evidence of substantial improvement over existing options. Priority Review means the FDA can take action on an application within 6 months, instead of a standard review of 10 months.

Fintepla is a low-dose oral solution of fenfluramine hydrochloride. The therapy is given with other treatments to reduce the frequency of epileptic seizures. Fintepla is currently being tested in three Phase 3 clinical studies — ZX008-1501 (NCT02682927), ZX008-1502 (NCT02826863), and the open-label extension study (NCT02823145). The ZX008-1502 trial is currently recruiting participants; more information can be found on the trial’s page.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Disclaimer:

Dravet Syndrome News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more